Dr Reddy’s Labs Announces Commercial Launch Of Covid19 Drug 2-DG, MRP Of Each Sachet Fixed At ₹990

Dr Reddy’s Laboratories has announced the commercial launch of 2-deoxy-D-glucose (2-DG), a drug for moderate to severe Covid-19 patients administered as an adjunct therapy to the existing standard care.

2-DG was developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy’s Labs.

The emergency use approval for anti-Covid-19 therapeutic application of the drug was granted on May 1, 2021.

2-DG manufactured by Dr Reddy’s has a purity of 99.5 per cent and is being sold commercially under the brand name 2DGTM. The maximum retail price (MRP) of each sachet has been fixed at ₹990, with a subsidised rate offered to government institutions.

The oral drug can be administered only upon prescription and under the supervision of a qualified physician to hospitalised patients.

Also Read -DRDO Developed '2-DG' Drug Inhibits Coronavirus Multiplication, Likely To Work Against All COVID Variants: Study